Summary
For Year 2026-27, Orchid Pharma reports the following shareholding: Total Promoters at 69.84%, Mutual Fund at 19.43%, Insurance at 0.09%, Foreign Institutional Investors at 0.87%, Domestic Institutional Investors at 0.73%, and Retail at 9.05%. This breakdown provides a quick snapshot of ownership distribution for Orchid Pharma in 2026-27.
Orchid Pharma FAQs
As of 05-2026, the promoter shareholding in Orchid Pharma stands at 69.84% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Orchid Pharma is 0.87% and 0.73% respectively.
The retail shareholding of the Orchid Pharma is 9.05%.
Changes in shareholding patterns of Orchid Pharma can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Orchid Pharma are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
